22.30NOK+1.36%Mkt Cap: 62.25M $P/E: —Today
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
| Headline | Source | Time |
|---|---|---|
Today | ||
Yesterday | ||
This week | ||
Older | ||
IInvestornytt | ||
Zelluna ASA (OSL:ZLNA) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Insights Zelluna ASA (OSL:ZLNA) reports strong capital raise, strategic clinical advancements, and financial challenges in its Q3 2025 earnings call. | ||
Zelluna ASA (OSL:ZLNA) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... Zelluna ASA (OSL:ZLNA) progresses towards clinical trials despite financial hurdles, with promising developments in its TCR-NK platform. | ||